Objectives To evaluate the efficacy and long-term outcomes of plug-assisted retrograde transvenous obliteration (PARTO) for the treatment of medically refractory hepatic encephalopathy (HE). Materials and methods Fifty-eight patients with cirrhosis who presented with one or more types of large portosystemic shunt (PSS) between April 2009 and March 2023 and had a history of at least two episodes of recurrent HE in the preceding 6 months were included in this retrospective study. Clinical follow-up included venous ammonia and West Haven (WH) score assessment. Technical and long-term outcomes were reviewed and analyzed. Results The technical success rate was 98.3% (57 of 58 patients). The mean procedure time was 29 min (range, 9–114 min). The immediate clinical success rate was 98.3%. The median WH score improved significantly from 2 (range, 1–3) pre-PARTO to 0 (range, 0–1) post-PARTO (p < 0.001). The mean serum ammonia level, which was 82.4 µmol/dL ± 46 before PARTO, decreased significantly to 23.7 µmol/dL ± 17 within 1 week after PARTO (p < 0.001). Long-term follow-up data were available for only 48 patients because of early death (n = 2), follow-up loss (n = 2), or liver transplantation (n = 5). The obliteration rate of PSS was 100%. Nine (18.8%) patients experienced recurrence of HE at a mean of 19.6 months (range 1.5–32.8 months). The cumulative 1-, 2-, 3-, 5-, and 10-year recurrence rates of HE were 6.4%, 14.9%, 27.5%, 27.5%, and 27.5%, respectively. The median transplantation-free survival time was 45.7 months (95% confidence interval, 25–66.5 months). Conclusion High clinical success rate and low recurrence rate of HE during the long-term follow-up period suggest that PARTO is an effective treatment for refractory HE due to PSS in patients with liver cirrhosis. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> The efficacy and long-term outcomes of plug-assisted retrograde transvenous obliteration for patients with hepatic encephalopathy have not yet been strictly determined. <Emphasis Type="BoldItalic">Findings</Emphasis> The clinical symptoms of hepatic encephalopathy completely resolved in 57 (98.3%) of 58 patients within 2 days after plug-assisted retrograde transvenous obliteration. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> Long-term outcomes suggest that plug-assisted retrograde transvenous obliteration is an effective treatment for refractory hepatic encephalopathy due to portosystemic shunt in patients with liver cirrhosis. Graphical Abstract

Long-term outcomes of plug-assisted retrograde transvenous obliteration (PARTO) for refractory hepatic encephalopathy

期刊论文
发表日期：

2025年7月16日

查看全文

Dong II Gwon,
Gun Ha Kim,
Hee Ho Chu,
Jihoon Kim,
Byoung Soo Im,
Eunbyeol Ko,
Jeongyeon Kim,
Jin Hyoung Kim,
Gi-Young Ko,
Hyun-Ki Yoon

摘要

Objectives

To evaluate the efficacy and long-term outcomes of plug-assisted retrograde transvenous obliteration (PARTO) for the treatment of medically refractory hepatic encephalopathy (HE).

Materials and methods

Fifty-eight patients with cirrhosis who presented with one or more types of large portosystemic shunt (PSS) between April 2009 and March 2023 and had a history of at least two episodes of recurrent HE in the preceding 6 months were included in this retrospective study. Clinical follow-up included venous ammonia and West Haven (WH) score assessment. Technical and long-term outcomes were reviewed and analyzed.

Results

The technical success rate was 98.3% (57 of 58 patients). The mean procedure time was 29 min (range, 9–114 min). The immediate clinical success rate was 98.3%. The median WH score improved significantly from 2 (range, 1–3) pre-PARTO to 0 (range, 0–1) post-PARTO (p < 0.001). The mean serum ammonia level, which was 82.4 µmol/dL ± 46 before PARTO, decreased significantly to 23.7 µmol/dL ± 17 within 1 week after PARTO (p < 0.001). Long-term follow-up data were available for only 48 patients because of early death (n = 2), follow-up loss (n = 2), or liver transplantation (n = 5). The obliteration rate of PSS was 100%. Nine (18.8%) patients experienced recurrence of HE at a mean of 19.6 months (range 1.5–32.8 months). The cumulative 1-, 2-, 3-, 5-, and 10-year recurrence rates of HE were 6.4%, 14.9%, 27.5%, 27.5%, and 27.5%, respectively. The median transplantation-free survival time was 45.7 months (95% confidence interval, 25–66.5 months).

Conclusion

High clinical success rate and low recurrence rate of HE during the long-term follow-up period suggest that PARTO is an effective treatment for refractory HE due to PSS in patients with liver cirrhosis.

Key Points

Question The efficacy and long-term outcomes of plug-assisted retrograde transvenous obliteration for patients with hepatic encephalopathy have not yet been strictly determined.

Findings The clinical symptoms of hepatic encephalopathy completely resolved in 57 (98.3%) of 58 patients within 2 days after plug-assisted retrograde transvenous obliteration.

Clinical relevance Long-term outcomes suggest that plug-assisted retrograde transvenous obliteration is an effective treatment for refractory hepatic encephalopathy due to portosystemic shunt in patients with liver cirrhosis.

Graphical Abstract